Importance of formalin fixing conditions for HER2 testing in gastric cancer: immunohistochemical staining and fluorescence in situ hybridization by Yoriko Yamashita-Kashima et al.
ORIGINAL ARTICLE
Importance of formalin fixing conditions for HER2 testing
in gastric cancer: immunohistochemical staining and fluorescence
in situ hybridization
Yoriko Yamashita-Kashima • Sei Shu • Keigo Yorozu •
Kaoru Hashizume • Yoichiro Moriya • Kaori Fujimoto-Ouchi •
Naoki Harada
Received: 21 May 2013 / Accepted: 16 December 2013 / Published online: 12 January 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract
Background Accurate and reliable assessment of human
epidermal growth factor receptor type 2 (HER2) status is
important for selecting patients with gastric cancer who
may benefit from trastuzumab treatment. Here we exam-
ined the impact of formalin fixing conditions on HER2
immunohistochemistry (IHC) and fluorescence in situ
hybridization (FISH) in xenografted tumor tissues.
Methods Xenografted tumor tissues of the human gastric
cancer cell lines NCI-N87, SCH, and SNU-16 were col-
lected and kept at room temperature for 0, 6, or 24 h before
being fixed with 10 % neutral buffered formalin (NBF) for
24 h or 5, 7, or 10 days and embedded in paraffin. Use of
10 % NBF, 20 % NBF, or nonbuffered formalin as fixative
was investigated.
Results The HER2 IHC scores for NCI-N87, SCH, and
SNU-16 tumors were 3?, 2?, and 1?, respectively, when
specimens were fixed with 10 % NBF for 24 h immedi-
ately after resection of the tumors. Specimens left for
longer than 6 h before fixation had shrinkage of the tumor
periphery and decreased immunostaining intensity in this
region in all specimens. In SCH and SNU-16 specimens,
starting fixation 24 h after tumor tissue collection induced
autolysis and reduction of the number of stained cells, and
10-day-fixation lowered the HER2 score. Prolongation of
fixation time did not affect FISH results, but if samples
were left for more than 6 h before fixation, the FISH score
was strongly reduced in SCH specimens (2.3 to 1.3).
Reduced IHC staining intensity was observed with 20 %
NBF and nonbuffered formalin compared to 10 % NBF.
Conclusions The time to and length of fixation of tumor
specimens can affect HER2 IHC and FISH scores. The
fixative used can affect IHC results.
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Introduction
Gastric cancer is the forth frequently diagnosed tumors in
the world with 989,000 cases estimated to have occurred
[1] and is the second leading cause of cancer death
worldwide (738,000 deaths; 9.7 % of all cancers) as of
2008 [1]. Although fluoropyrimidine- or platinum-based
combination chemotherapy are the most widely accepted
regimens for advanced gastric cancer in the world at
present, their benefit has not necessarily been translated
into higher overall survival rates. The addition of the
HER2-targeted agent trastuzumab to these standard che-
motherapy regimens has been investigated for patient with
HER2-positive disease. HER2, a member of the HER
family proteins, regulates cell proliferation, differentia-
tion, and apoptosis. These functions are triggered by the
formation of HER2 homodimers or heterodimers with
other HER family proteins [2] and subsequent activation
of downstream signaling. In breast cancer, HER2 over-
expression is a prognostic factor [3–5] and an important
predictive marker for determining which patients are
likely to benefit from treatment with trastuzumab. In
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gastric cancer, there is controversy concerning whether
HER2 status provides prognostic information [6]. How-
ever, it is necessary to determine HER2 status to deter-
mine whether trastuzumab will be a beneficial option for
patients.
The ToGA trial, an open-label, international, phase III,
randomized controlled trial, demonstrated that patients
with HER2-positive gastric cancer assigned to receive
trastuzumab plus standard chemotherapy had significantly
longer overall survival (OS) (hazard ratio: HR 0.74, 95 %
CI, 0.60–0.91) compared with patients with HER2-positive
gastric cancer assigned to receive chemotherapy alone [7].
The improvement in OS in the trastuzumab arm was more
apparent in patients whose tumors had high HER2
expression [immunochemistry (IHC) 3?, or IHC 2? and
fluorescence in situ hybridization (FISH) positive], with a
HR of 0.65 (95 % CI, 0.51–0.83). Based on the results of
the ToGA study, regimens that include trastuzumab plus
chemotherapy became a new standard treatment modality
for HER2-positive gastric cancer.
Immunohistochemistry analysis, which evaluates pro-
tein expression, and FISH analysis, which evaluates gene
amplification, are major methods for HER2 testing.
Although assessing HER2 status accurately and reliably is
of great importance to determine whether patients have
HER2-positive breast or gastric cancer, there is variability
of sample preparation for HER2 testing [8]. A number of
reports show discordance in HER2 testing results between
laboratories [9, 10]. Perez et al. [11] have shown the
importance of using high-volume, experienced laboratories
for HER2 testing to improve the process of selecting
patients likely to benefit from trastuzumab therapy. To
ensure accurate evaluation, the American Society of Clin-
ical Oncology (ASCO) and College of American Patholo-
gists (CAP) implemented guidelines for HER2 evaluation
in breast cancer in 2007 [12].
By virtue of the ASCO/CAP guidelines, the method of
preparing specimens has been standardized in breast can-
cer. In Japan, HER2 testing guidelines for gastric cancer
were defined by the trastuzumab pathological advisory
board for gastric cancer in line with ASCO/CAP guide-
lines. Paraffin sections are prepared, and the IHC scoring
system is used according to these criteria that aimed to
develop a validated HER2 scoring system for gastric can-
cer [13]. However, interlaboratory differences in the results
of HER2 testing are still a considerable problem in gastric
cancer, and one cause may be inappropriate preparation of
formalin-fixed paraffin-embedded tissues. In the present
study, we investigated the effect of formalin fixing condi-
tions, including time to fixation, fixation time, and com-
position of fixatives, on IHC and FISH for HER2 using
human gastric cancer cell line xenografted tumor tissues
with different HER2 status.
Materials and methods
Animals
Five-week-old male BALB-nu/nu mice (CAnN.Cg-
Foxn1\nu[/CrlCrlj nu/nu) were obtained from Charles
River Laboratories Japan (Yokohama, Japan). All animals
were housed in a pathogen-free environment under con-
trolled conditions (temperature 20–26 C, humidity
40–70 %, light:dark cycle 12/12 h). Chlorinated water and
irradiated food were provided ad libitum. All animals were
allowed to acclimatize and recover from shipping-related
stress for 1 week before the study. The health of the mice
was monitored by daily observation. All animal experi-
ments were conducted in accordance with the Guidelines
for the Accommodation and Care of Laboratory Animals
promulgated in Chugai Pharmaceutical Co., Ltd.
Cell lines and culture conditions
Three human gastric cancer cell lines were used in the
present study. NCI-N87 and SNU-16 cells were purchased
from American Type Culture Collection (ATCC) (Rock-
ville, MD, USA). SCH cells were purchased from Japan
Health Sciences Foundation (Osaka, Japan). NCI-N87,
SNU-16, and SCH were maintained in RPMI-1640 (Sigma-
Aldrich, St. Louis, MO, USA) supplemented with 10 % (v/
v) fetal bovine serum at 37 C under 5 % CO2. The his-
tological type of each cell line is shown in Table 1.
Preparation of specimens
Each mouse was inoculated subcutaneously into the right
flank with 5 9 106 cells/mouse of a human gastric cancer
cell line, either NCI-N87, SCH, or SNU-16. Tumor xeno-
graft tissues were collected and allowed to stand at room
temperature for 0, 6, or 24 h before being fixed with 10 %
neutral buffered formalin (NBF) for 24 h, or 5, 7, or
10 days, and then embedded in paraffin. To compare the


















a Histological type was described according to the information from
each cell line distributor
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effect of fixing solution on HER2 IHC, 10 % NBF, 20 %
NBF, 10 % nonbuffered formalin, or 20 % nonbuffered
formalin was used. Specimens were prepared from two
separate tumors from mice inoculated with NCI-N87 and
SNU-16 and three tumors from SCH-inoculated mice.
IHC, gene amplification of HER2, and histological
assessment
HER2 protein expression and HER2 gene amplification in
tumors were examined by IHC using HercepTest (Dako,
Glostrup, Denmark) and by FISH using PathVysion HER2
DNA Probe (Abbott Molecular, Abott Park, IL, USA),
respectively, at SRL (Tokyo, Japan) as described previ-
ously [14]. Histological assessment was performed under a
light microscope.
Results
IHC and FISH status of tumor tissues used
Three tumor tissues with different HER2 status were used in
this study. The HER2 status of these tumor tissues were
assessed by IHC and FISH, using specimens fixed with 10 %
NBF for 24 h immediately after resection of the tumors. The
IHC scores for NCI-N87, SCH, and SNU-16 were 3?, 2?,
and 1?, respectively, and HER2/CEP17 ratios by FISH were
8.4, 2.3, and 1.4, respectively (Table 1).
Effect of time to fixation and fixation time on IHC
staining for HER2
First, we examined the effect of time to fixation and length
of fixation on IHC staining for HER2 in NCI-N87, SCH,
and SNU-16 tumor tissues. Leaving specimens for 6 or
24 h before fixation at room temperature promoted
shrinkage in the tumor tissue periphery and decreased
immunostaining intensity at the shrinkage area in tumors
from all the cell lines, irrespective of HER2 status and
fixation time (Fig. 1a–c; Tables 2, 3). In SCH or SNU-16
tumors, leaving the specimens for 24 h before fixation also
induced autolysis and decreased the number of stained cells
in the center of tumor tissues (Fig. 2a, b; Table 3). As a
result, the total staining intensity and total staining area
were decreased in these two tumors. In SCH tumors, a
decrease of the HER2 IHC score to 1? was observed in
two of three specimens left for 24 h and then fixed for 24 h
(Table 2).
Second, we examined the effect of fixation time on IHC
staining for HER2. In NCI-N87 specimens from tumors
with a HER2 IHC 3? score, there was no change in HER2
IHC score (Fig. 3a; Table 2). However, in SCH or SNU-16
specimens from tumors with HER2 IHC 2? or 1? scores,
the scores were decreased to 1? or 0, respectively, in one
of three or one of two specimens by fixing for 10 days,
even when fixation was started immediately after the tumor
collection (Fig. 3b, c; Table 2). Moreover, in SNU-16
tumor specimens that were left for 24 h before fixation,
prolonged fixation time (10-day fixation) promoted the
decrease of HER2 staining intensity at the shrunken area
and a decrease in HER2-positive cells (Table 3). HER2
IHC scores for these specimens were 0 in all specimens
(two of two) (Table 2).
Effect of time to fixation and fixation time on FISH
results
We also investigated whether delay to formalin fixation or
prolonged fixation time affects FISH results. SCH speci-
mens in which time to fixation and fixation time were (1) 0
and 24 h, (2) 0 h and 10 days, (3) 6 and 24 h, (4) 24 and
24 h, or (5) 24 h and 10 days were assessed by FISH
(HER2/CEP17 ratio). The mean of the HER2/CEP17 ratios
of specimens of times (1), (2), (3), (4), and (5) were 2.3, 2.6,
1.3, 1.2, and 1.1, respectively, suggesting that prolonged
fixation time did not affect the FISH results but that delay to
fixation strongly reduced the FISH score (Table 4).
Effect of fixative type on IHC staining for HER2
The type of fixative used for the preparation of specimens
may be another important factor affecting the concordance
of HER2 testing results. Therefore, we next examined the
effect of fixative type on IHC staining for HER2. In this
experiment, we used first specimens of the SCH tumor
(HER2 IHC score 2?) because, in clinical specimens, those
judged as HER2 IHC score 2? are considered to be
equivocal and the FISH test is recommended to make a final
diagnosis for trastuzumab application. Therefore, it makes
sense to examine whether fixative type affects the results of
the HER2 IHC test in tumor tissue specimens of HER2 IHC
score 2?. For this purpose, we used 10 % NBF, 20 % NBF,
10 % nonbuffered formalin, or 20 % nonbuffered formalin.
The tumor tissues were fixed with each fixative immediately
after collecting. Fixing with 20 % NBF, or 10 % or 20 %
nonbuffered formalin for 24 h reduced the staining intensity
of HER2 and reduced the HER2 IHC score from 2? to 1?
in one of three specimens compared to fixing with 10 %
NBF (Fig 4; Table 5). When tumor tissues were fixed for
10 days, the reduction in HER2 staining intensity was more
apparent, and an HER2 IHC score reduction was observed in
two of three specimens in 20 % NBF and 10 % nonbuffered
formalin and in three of three specimens in 20 % nonbuf-
fered formalin (Table 5). These results indicate that all
formalin fixatives used, other than 10 % NBF, could
640 Y. Yamashita-Kashima et al.
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negatively affect the results of HER2 IHC staining in tumors
with HER2 IHC score 2?. Second, we examined the effect
of fixative type on HER2 IHC staining using specimens of
NCI-N87 tumor (HER2 IHC score 3?) in the same way as
already described. We found that all four fixatives did not
affect the results of HER2 IHC staining in either 24-h or
10-day fixation (Table 6).
Discussion
In breast cancer, ASCO/CAP issued guidelines to stan-
dardize fixation for increased HER2 testing accuracy. In
addition, many investigations into the optimal conditions
for accurate HER2 testing have been conducted [15–18].
Delay to formalin fixation after specimen collection and
extended fixation times may affect HER2 testing results.
Several reports have shown the effect of time to fixation,
fixation time, or fixative type on IHC or FISH for HER2.
Khoury et al. [16] reported that more than a 1-h delay to
formalin fixation negatively affected the HER2 IHC and
FISH results. However, Moatamed et al. [18] showed that
ischemic time (with a delay in fixation of 4 days at 4 C),
fixation time (0–168 h), and fixative type did not signifi-
cantly alter HER2 IHC and FISH results. Thus, even in
breast cancer, it may be considered that more studies are
required to determine the most appropriate procedure for
HER2 testing that can be applied in every laboratory.
Needless to say, it is also important in gastric cancer to
assess HER2 status accurately and reliably. However, there
are no reports of analyzing formalin fixing conditions on
HER2 testing in gastric cancer. In the present study, we
investigated how the fixation conditions of specimens
affected HER2 IHC and FISH results using paraffin-
embedded gastric cell line xenografted specimens prepared
using various fixation conditions. To prepare the specimens
in guideline-recommended conditions, we made paraffin-
embedded specimens in accordance with HER2 testing
guidelines defined by the trastuzumab pathological advi-
sory board for gastric cancer.
bFig. 1 Effect of time to fixation on immunohistochemistry (IHC)
staining for HER2 in tumor tissue periphery. Tumor tissue specimens
of NCI-N87 (a), SCH (b), or SNU-16 (c) were collected and allowed
to stand for 0, 6, or 24 h before fixing with 10 % neutral buffered
formalin (NBF) for 24 h. Upper panels HER2 IHC staining; lower
panels hematoxylin and eosin staining. Arrows indicate shrunken
areas and areas of decreased staining intensity. Bars 50 lm
Table 2 Effect of fixation conditions on HER2 immunochemistry (IHC) score in human breast cancer xenografted tumors
Time to fixation NCI-N87 SCH SNU-16
Fixation time Fixation time Fixation time
24 h 5 days 7 days 10 days 24 h 5 days 7 days 10 days 24 h 5 days 7 days 10 days
0 h 3? 3? 3? 3? 2?a 2?a 2?a 1?/2? 1? 1? 1? 0/1?
6 h 3? 3? 3? 3? 2? 2?/3? 2? 2? 1? 1? 1? 0/1?
24 h 3? 3? 3? 3? 1?/2? 1?a 1?/2? 1?/2? 1? 0/1? 1? 0
HER2 IHC was performed by HercepTest
Tests were performed in duplicate for NCI-N87 and SNU-16, in triplicate or duplicate (a) for SCH. If the test results of duplicate samples were
different, both values were indicated
Table 3 Effect of fixation conditions on the detailed histological assessment of HER2 IHC staining in human breast cancer xenografted tumors
Time to fixation NCI-N87 SCH SNU-16
Fixation time Fixation time Fixation time
24 h 5 days 7 days 10 days 24 h 5 days 7 days 10 days 24 h 5 days 7 days 10 days
0 h – – – – –g –g –g –/? – ? ? ?/??
6 h ± ± ± ± –/± ± –/± –/± ± ±/? ? ?/??
24 h ± ±/? ±/? ± ? ?g ±/? ±/? ? ?/?? ? ??/???
Histological assessment of decrease in staining was performed in terms of the following criteria and judged in a comprehensive manner:
(a) tumor periphery shrinkage (dry), (b) decrease of staining intensity at shrinkage area, (c) autolysis, (d) decrease in positive cells, (e) decrease
of total staining intensity, (f) decrease of total staining area
Assessments were performed in duplicate for NCI-N87 and SNU-16, in triplicate or duplicate (g) for SCH. If the results of duplicate or triplicate
samples were different, all results were indicated
–, no change; ±, very slightly decreased; ?, slightly decreased; ??, moderately decreased; ???, markedly decreased
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In the present study, leaving specimens at room tem-
perature for more than 6 h before fixation led to shrinkage
at the tumor periphery and decreased the staining
intensity at the shrinkage area in all the tumors assessed,
irrespective of HER2 status. However, a decrease in
HER2 IHC score was observed only in SCH specimens
Fig. 2 Effect of time to fixation
on IHC staining for HER2 in
tumor tissue center. Tumor
tissue specimens of SCH (a) and
(b) SNU-16 were collected and
allowed to stand for 0 or 24 h
before fixing with 10 % NBF
for 24 h. Upper panels HER2
IHC staining; lower panels
hematoxylin and eosin staining.
Arrows indicate areas of
advanced autolysis. Bars 50 lm
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Fig. 3 Effect of fixation time
on IHC staining for HER2.
Tumor tissue specimens of NCI-
N87 (a), SCH (b), and SNU-16
(c) were collected and
immediately fixed with 10 %
NBF for 24 h or 10 days. Upper
panels HER2 IHC staining;
lower panels hematoxylin and
eosin staining. Bars 50 lm
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with a 24-h delay to fixation, whereas the HER2/CEP17
ratio of FISH in SCH was decreased from 2.3 to 1.3 if the
tumor sample was left at room temperature for only 6 h
before fixation. In breast cancer, it has been reported that
a delay to formalin fixation affects FISH results but not
IHC scores [16]. Therefore, we would expect that FISH
results would be more vulnerable to delayed fixation than
IHC in gastric cancer specimens.
With regard to fixation time, prolonged fixation did not
affect the HER2 IHC scores of NCI-N87 tumors (HER2 3?
score) (Table 2). However, in the specimens in which
HER2 scores were 2? (SCH) or 1? (SNU-16), prolonged
fixation reduced the HER2 IHC score (Table 2). These
results correspond well to the report of Hashizume et al.
[15], who showed that prolonged fixation affects HER2
IHC score in 2? or 1? breast cancer specimens. Our
results suggest that considerable attention should be paid to
the time elapse from excision to fixation and the fixation
time of tumor tissues in gastric cancer as well as breast
cancer.
The present study using several types of fixatives
showed that with fixatives other than 10 % NBF IHC
staining of HER2 in SCH (IHC score 2?) was reduced.
We also examined the effect of fixatives in NCI-N87 (IHC
score 3?); however, there were no differences in staining
between fixatives. Staining of specimens that moderately
Fig. 4 Effect of fixative type on IHC staining for HER2. SCH tumor tissues were collected and immediately fixed with 10 % NBF, 20 % NBF,
10 % nonbuffered formalin, or 20 % nonbuffered formalin for 24 h. Bars 100 lm
Table 4 Effect of fixation conditions on HER2 FISH in SCH xeno-
grafted tumors
Time to fixation Fixation time HER2/CEP17 ratio (FISH)
0 h 24 h 2.3
0 h 10 days 2.6
6 h 24 h 1.3
24 h 24 h 1.2
24 h 10 days 1.1
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express HER2 protein may therefore be affected more
easily by the type of fixative used compared to staining of
specimens with high expression of HER2. In the present
study, we did not examine the effect of fixative type on
FISH results, because, for gastric cancer, IHC testing is
recommended as a first examination for HER2, followed
by confirmative testing by FISH for IHC score 2?
specimens.
In the clinical setting, it is important to take unique
HER2 staining characteristics into consideration when
standardizing HER2 testing in gastric cancer. One such
characteristic is the heterogeneity defined as less than 30 %
of tumor cells staining positive or only focal staining of
tumor cells [13, 19]. Gastric cancer exhibits heterogeneity
in up to 30 % of HER2-positive cases [19]. The other
consideration is that HER2-positive gastric carcinomas are
usually of the gland-forming, intestinal type and may show
incomplete, basolateral, or lateral membranous staining
[20]. In the present study, we used xenografted tumors
from mouse models as specimens that did not reflect the
heterogeneity or other staining features of human gastric
cancer. Therefore, in clinical cases, the impact of formalin
fixing conditions on the results of IHC staining or FISH for
HER2 may not be the same as in the present study. Further
study is required in a clinical setting.
In conclusion, our results indicate that delay to fixation
and length of fixation may affect the HER2 IHC score in a
gastric cancer model. Nonbuffered formalin or high con-
centrations of neutral buffered formalin (NBF) may also
affect IHC results. These results highlight that it is of
critical importance to optimize sample preparation condi-
tions for HER2 testing in gastric cancer.












24 h HER2 IHC scorea 2? 1?/2? 1?/2? 1?/2?
Histological assessment/decrease in
stainingb
– –/? –/? –/?
10 days HER2 IHC scorea 2? 1?/2? 1?/2? 1?
Histological assessment/decrease in
stainingb
– –/? –/? ?
Tests and assessments were performed in triplicate. If the test results of triplicate samples were different, all results were indicated
a HER2 IHC was performed by HercepTest
b Histological assessment on the decrease in staining was performed in terms of the following criteria and judged in a comprehensive manner:
(a) autolysis, (b) decrease in positive cells, (c) decrease of total staining intensity, (d) decrease of total staining area
–, no change; ±, very slightly decreased; ?, slightly decreased; ??, moderately decreased; ???, markedly decreased












24 h HER2 IHC scorea 3? 3? 3? 3?
Histological assessment/decrease in
stainingb
– – – –
10 days HER2 IHC scorea 3? 3? 3? 3?
Histological assessment/decrease in
stainingb
– – – –
Tests and assessments were performed in duplicate
a HER2 IHC was performed by HercepTest
b Histological assessment on the decrease in staining was performed in terms of the following criteria and judged in a comprehensive manner:
(a) autolysis, (b) decrease in positive cells, (c) decrease of total staining intensity, (d) decrease of total staining area
-, no change, ±, very slightly decreased; ?, slightly decreased, ??, moderately decreased; ???, markedly decreased
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